Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Machines

Description

The Trust is looking to purchase new specialised licensed system for HIPEC delivery that is suitable for administration and circulation of heated cytotoxic drugs into an intubated patient during cytoreductive surgery. Lot 1: The Christie is an NHS Tertiary level cancer centre, providing a whole range of cancer therapies for a broad range of oncological disease both solid tumour and Haematology. Surgeons from the Colorectal and Peritoneal Oncology Centre (CPOC) perform Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) procedures in five Trust theatres, and in other theatre facilities operated by an on-site commercial partner.<br/> <br/>As a leading centre, the Trust is looking to invest in upgraded technology for the delivery of HIPEC as part of a programme to increase activity and lead innovation of the use of this technique.<br/> <br/>The Trust is looking to purchase new specialised licensed system for HIPEC delivery that is suitable for administration and circulation of heated cytotoxic drugs into an intubated patient during cytoreductive surgery. The new equipment must be:<br/>1. Intuitive to set-up and suitable for use in a high-throughput environment - assembly, maintenance, heating, cleaning, and decontamination, and facilitate effective troubleshooting for the user.<br/>2. Provide onboard real-time monitoring temperature and other parameters such as circulation pressures within the peritoneal cavity.<br/>3. Capable of offering users a high level of control of temperature - Capable of maintaining the fluid circulation at 42 degrees to ensure the abdomen is maintained at a uniform temperature. Including the ability to monitor temperature at a minimum of 5 varying points. Temperature must be adjustable to adapt to patient parameters throughout the procedure without pausing treatment.<br/>4. Capable of delivering at variable flow rates, optimum flow rate must be 1200ml/min circulation, with ability to adapt to patient parameters throughout the treatment, without pausing treatment. The ability to reverse flow during the procedure without pausing treatment is additionally required.<br/>5. The system is required to deliver 3L patient volume of circulation fluid.<br/>6. The system circuit should be visible and weighted to ensure any change in parameters can be noticeably identified.<br/>7. Safe - to ensure safety during use of cytotoxic drugs and other hazardous materials including bodily fluids, it is essential that the equipment is designed to minimise the risk of spillage by use of a closed system single use circulation kit.<br/>8. Reliable and user-friendly - with a strong track record of use within centres offering this treatment with reputable practice. The manufacturer must be able to provide perfusion training and troubleshooting guidance when required. With experience of this form of support to centres within the United Kingdom.<br/>9. Versatile, with control ‘in-procedure’ – as a leading treatment centre, the equipment should not limit the use of innovative techniques<br/>10. The device must hold the capability to reliably record treatment data that can be analysed and utilised for research/ measurable outcomes. <br/>11. The device must have the capability to facilitate a range of techniques used for HIPEC administration, primarily a closed technique, with ability to support both open and laparoscopic technique. <br/>The Christie has over the past two decades developed an established advanced approach to Cytoreductive surgery with HIPEC. The accompanying SOPs illustrate how HIPEC equipment is used to deliver safe and effective treatment. We invite prospective suppliers with an international reputation and network of supporting HIPEC to consider the compatibility of their equipment for this procedure.<br/> <br/>Also, as a world-leading centre for use of HIPEC, the Trust is interested in developing a mutually beneficial long-term collaboration with its chosen supplier of HIPEC devices, and would welcome proposals as to how such a collaboration might draw on the expertise of both parties to lead innovation in the use of HIPEC and promote its use nationally and internationally.<br/> <br/> The Trust invites interested suppliers to reply before the 31st October to indicate their interest in responding to this opportunity and to provide a 300 word outline of what they could propose. However suppliers who do not reply before this deadline will still be able to submit formal proposals when a full tender is released to the market.